Mu-type opioid receptor – Alpha-2A adrenergic receptor complex (MOR-α2AAR complex)

The Mu-type opioid receptor – Alpha-2A adrenergic receptor complex is a G protein-coupled receptor (GPCR) heteromer formed by the physical association of the mu-opioid receptor (MOR) and the alpha-2A adrenergic receptor (α2AAR) (Jordan et al., 2003, Nature). This complex is predominantly localized in the dorsal horn of the spinal cord and other CNS regions critical for nociceptive processing (Riedl et al., 2009, PNAS). The heteromerization results in unique signaling properties, including synergistic antinociceptive effects when both receptors are activated simultaneously (Vilardaga et al., 2008, Nature Chemical Biology). This phenomenon is widely exploited in clinical pain management through the co-administration of opioids and alpha-2 agonists to achieve better pain control with lower doses. Furthermore, the complex exhibits cross-conformational changes where the binding of a ligand to one protomer can allosterically modulate the affinity or efficacy of the other (Vilardaga et al., 2008, Nature Chemical Biology). Research indicates that the MOR-α2AAR complex plays a significant role in the development of opioid tolerance and hyperalgesia. Targeting this specific heteromer with bivalent ligands represents a promising strategy for developing next-generation analgesics. These novel compounds aim to provide potent pain relief while minimizing common side effects such as respiratory depression and sedation.

Other names

MOR-alpha2AAR heteromerMu-opioid receptor-alpha-2A-adrenoceptor complexOPRM1-ADRA2A complexMOR-ADRA2A complex

Synergistic Gi/o protein activation and allosteric cross-talk between the mu-opioid and alpha-2A adrenergic protomers (Vilardaga et al., 2008, Nature Chemical Biology).